Insulet Corporation (GOV)
Summary
GOV Chart
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
Insulet Corporation (PODD) Q2 2026 Earnings Call Transcript
Insulet Corporation (PODD) Q2 2026 Earnings Call Transcript
Insulet Q2 Earnings Call Highlights
Insulet NASDAQ: PODD reported second-quarter revenue growth of 23% on a constant-currency basis, supported by demand for its Omnipod insulin-delivery system in the U.S. and international markets, while raising its international outlook and reducing its U.S. and total-company revenue-growth expectations for 2026.
Insulet Corporation (GOV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Insulet Corporation ever had a stock split?
Insulet Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Ashley McEvoy CEO | XMUN Exchange | US45784P1012 ISIN |
| US Country | 5,400 Employees | - Last Dividend | - Last Split | 15 May 2007 IPO Date |
Overview
Insulet Corporation is a pioneering healthcare company that specializes in the development, manufacturing, and sale of innovative insulin delivery systems intended primarily for individuals with insulin-dependent diabetes. Founded in the year 2000 and with its headquarters located in Acton, Massachusetts, Insulet Corporation aims to improve the quality of life for people living with diabetes through its cutting-edge products. The company markets its solutions across a broad geographic spectrum including the United States, Canada, Europe, the Middle East, Australia, and other international markets, leveraging both direct sales and a network of independent distributors and pharmacy channels.
Products and Services
- Omnipod 5 Automated Insulin Delivery System (Omnipod 5)
The Omnipod 5 stands out as a flagship offering from Insulet Corporation, showcasing a proprietary Automated Insulin Delivery (AID) algorithm built into the Pod. This system is designed to seamlessly integrate with a third-party continuous glucose monitor (CGM), with the aim of obtaining glucose readings via wireless Bluetooth communication. This integration facilitates a dynamic adjustment of insulin delivery, aiming to maintain glucose levels within the target range, hence offering a sophisticated solution to insulin management.
- Omnipod DASH
Omnipod DASH elevates the convenience of insulin delivery systems by featuring a Bluetooth-enabled Pod, which is managed through a user-friendly Personal Diabetes Manager (PDM). The PDM, resembling a smartphone in its design, comes equipped with a color touch screen user interface. This system provides users a blend of advanced technology and ease of use, making daily diabetes management more manageable and less intrusive.
- Omnipod GO
The Omnipod GO system introduces a standalone, wearable insulin delivery solution that administers a fixed rate of continuous rapid-acting insulin over a duration of 72 hours. This system is tailored for those seeking simplicity and effectiveness in their insulin therapy, catering especially to individuals who prefer a straightforward approach to diabetes management without the need for frequent adjustments.
